Navigation Links
Blocking rogue gene could stop the spread of most cancers

Scientists at the University of East Anglia (UEA) have discovered a rogue gene which if blocked by the right drugs could stop cancer in its tracks.

Published today by the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.

The culprit gene known as WWP2 - is an enzymic bonding agent found inside cancer cells. It attacks and breaks down a natural inhibitor in the body which normally prevents cancer cells spreading. The UEA team found that by blocking WWP2, levels of the natural inhibitor are boosted and the cancer cells remain dormant. If a drug was developed that deactivated WWP2, conventional therapies and surgery could be used on primary tumours, with no risk of the disease taking hold eleswhere.

Lead author Andrew Chantry, of UEA's School of Biological Sciences, said the discovery could lead to the development of a new generation of drugs within the next decade that could be used to stop the aggressive spread of most forms of the disease, including breast, brain, colon and skin cancer.

"The late-stages of cancer involve a process known as metastasis - a critical phase in the progression of the disease that cannot currently be treated or prevented," said Dr Chantry.

"The challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene. This is a difficult but not impossible task, made easier by the deeper understanding of the biological processes revealed in this study."

The research was funded by UK-based charity the Association of International Cancer Research (AICR), with additional support from the Big C Charity and the British Skin Foundation.

Dr Mark Matfield, scientific co-ordinator of AICR, said: "This is a very exciting new discovery and a perfect example of the way that basic research into cancer can open up ways to develop new ways to treat cancer."

The initial discovery was made while researchers were studying a group of natural cancer cell inhibitors called 'Smads'.

Dr Surinder Soond, who spearheaded the experimental work in the laboratory, said: "This is a very novel and exciting approach to treating cancer and the spread of tumours which holds great potential."


Contact: Simon Dunford
University of East Anglia

Related biology news :

1. Blocking the critical structure that lets cancer cells move -- their feet
2. Tiny RNA molecules control labor, may be key to blocking premature birth
3. Cranberry juice shows promise blocking Staph infections
4. How blocking the Programmed Death 1 protein may treat or prevent sepsis and severe infection
5. Blocking cancer in its path: New cellular defect discovered
6. Blocking cell movement for cancer, MS treatment
7. Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
8. How do we kill rogue cells?
9. iGEM team helps prevent rogue use of synthetic biology
10. Oregons Rogue River Basin to face climate-change hurdles
11. Could oysters be used to clean up Chesapeake Bay?
Post Your Comments:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology: